Dec 17 (Reuters) - Imugene Ltd (IMU) :
- IMUGENE MEETS ENDPOINTS IN PHASE 1B GASTRIC CANCER IMMUNO-ONCOLOGY TRIAL
- NO SAFETY ISSUES WERE REPORTED AND HER-VAXX WAS FOUND TO BE WELL TOLERATED
News: IMU Imugene Meets Endpoints In Phase 1B Gastric Cancer Immuno-Oncology Trial
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.8¢ |
Change
-0.001(2.56%) |
Mkt cap ! $386.7M | |||
| Open | High | Low | Value | Volume |
| 3.8¢ | 3.9¢ | 3.8¢ | $134.8K | 3.498M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 23 | 1738258 | 3.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.9¢ | 494405 | 4 |
View Market Depth
| Last trade - 16.10pm 29/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |
